// // FDA Clears Neurovalens’s Modius Sleep for Insomnia Treatment | Knobbe Martens Skip to content
IP + Technology Law
Home  »  News & Insights  »  Blogs  »  Medical Devices & Procedures

FDA Clears Neurovalens’s Modius Sleep for Insomnia Treatment

November 7, 2023  | Mengmeng Du

Neurovalens successfully secured 510(k) clearance from the FDA on October 27, 2023 for its Modius Sleep device with relation to treatment of insomnia and/or anxiety.   The clearance was supported by data collected from a Phase III/pivotal clinical trial carried out in the UK and Ireland by Ulster University and in Hong Kong by PolyU University, Medical Device Network reports.  The 510(k) Premarket Notification also links to a clinical trial study titled Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus which started on May 21, 2021 and continues to run.

The Belfast-headquartered global health company was founded by Dr. Jason McKeown in 2015.  Neurovalens’s Modius Sleep device is a wearable headset that delivers non-invasive electrical stimulation to the vestibular nerve of the wearer’s brain, eliminating the need for surgically implanted electrodes.  According to Neurovalens, users should wear the Modius Sleep device for 30 minutes per day prior to going to bed for the electrical pulse to influence the areas of the hypothalamus and brain stem that control circadian rhythm and sleep patterns.  Besides insomnia and anxiety, type 2 diabetes and obesity are also current targets of the Neurovalens technology.

Related Links

Industries

News & Insights

Blog - Medical Devices & Procedures
Dec 2023
FDA Clears ABK Biomedical’s Eye90 Microspheres for Hepatocellular Carcinoma Treatment
ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of unresectable Hepatocellular Carcinoma (HCC). The FDA’s Breakthrough Device Program is designed to speed up the development, assessment, review for premarket approval, 510(k) clearance, and de novo marketing authorization of medical devices “that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.” This program replaces the FDA’s Expedited Access Pathway and Priority Review for medical devices. Clearance of the Eye90 device was supported by ABK Biomedical’s recently initiated Route90 trial, an FDA Investigational Device Exemption-supported multicenter trial. The trial evaluated tumor response rates and the duration of response in patients living with unresectable HCC from treatment with Eye90 microspheres.
Blog - Fashion & Beauty
May 2025
Fashion’s New Powerhouse: IP Lessons from Prada’s $1.375 Billion Versace Deal
On April 10, 2025, Italian fashion house Prada announced its acquisition of Versace from Capri Holdings for $1.375 billion, uniting two of Italy’s most iconic luxury brands.  Though financial implications...
Blog - Biotechnology
Apr 2025
U.S. Supreme Court Defers to Agency Decision-Making in FDA’s Denial of Premarket Approval of Flavored E-Cigarette Products
We previously reported a decision by the U.S. Food and Drug Administration (FDA), denying the premarketing authorization of several flavored e-cigarette product.[1]  On April 2, 2025, the Supreme Court of...